Loading organizations...
§ Private Profile · New Haven, CT, USA
A computational biotechnology company specializing in peptide drug discovery, applying computational methods for peptide therapeutics.
CMD Bioscience was a computational biotechnology company specializing in peptide drug discovery that operated from an undisclosed headquarters location during its active business lifecycle. The organization applied advanced computational methods and proprietary algorithms to identify, design, and develop novel peptide-based therapeutics intended for various complex medical applications. Operating exclusively within the broader life sciences and biotechnology sectors, the enterprise ultimately ceased its research operations and officially closed its business in 2015. Throughout its operational history, the firm did not publicly disclose specific details regarding its commercial customer base, lead institutional investors, or strategic pharmaceutical partnerships. Standard financial metrics and operational statistics, such as total venture funding raised, post-money valuation figures, and peak employee headcount, remain entirely unavailable in public market records. Consequently, the exact founding year and the specific identities of the original founders are not publicly documented.
CMD Bioscience has raised $1.0M across 1 funding round.
CMD Bioscience has raised $1.0M in total across 1 funding round.
CMD Bioscience has raised $1.0M in total across 1 funding round.
CMD Bioscience's investors include Daniel Wagner, Enhanced Capital, LaunchCapital, The Mohegan Tribe of Indians of Connecticut.
CMD Bioscience has raised $1.0M across 1 funding round. Most recently, it raised $1.0M Series A in December 2012.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 24, 2012 | $1M Series A | — | Daniel Wagner, Enhanced Capital, Launch Capital, The Mohegan Tribe OF Indians OF Connecticut | Announced |